FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy
StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]
Innovative Cell Therapy, Omisirge, Receives FDA Approval to Reduce Infection Risk in Blood Cancer Treatments
The FDA has approved Omisirge (omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to speed up the recovery of neutrophils and reduce infection risk. Omisirge is intended for use in adults and pediatric patients aged 12 and older with blood cancers who are undergoing umbilical cord blood transplantation after a myeloablative conditioning regimen. Blood […]
A New Hope: Umbilical Cord Blood Stem Cells Expand Access to HIV Cures
Mixed-race woman with both HIV and acute leukemia received a stem cell transplant using umbilical cord blood stem cells with a CCR5-delta32 mutation, which confers resistance to HIV. This modified approach may expand the pool of available stem cells for curing HIV in people needing transplants for other medical conditions. The patient’s leukemia remains in […]
Investing in Your Family’s Future: A Tour of CBR’s State-of-the-Art Stem Cell Facility
Dr. Ali Rodriguez has been invited by CBR to tour their state-of-the-art facility in Tucson, Arizona, which specializes in processing and storing umbilical cord stem cells. CBR, operational for 30 years, has processed nearly a million stem cell collections from families worldwide. Their 80,000 square foot laboratory, the largest newborn stem cell bank globally, uses […]